Ulcerative colitis (UC) and Crohn's disease (CD) [inflammatory bowel disease (IBD)] are both characterized by an exaggerated immune response at the gut associated lymphoreticular tissue level. Such an abnormal and dysregulated immune response may be directed against luminal and/or enteric bacterial antigens, as also supported by murine models of inflammatory bowel disease (IBD) caused by organisms such as Citrobacter rodentium and Helicobacter hepaticus.
Bacterial endotoxins or lipopolysaccharides (LPS) have been detected in the plasma of IBD patients and an abnormal microflora and/or an increased permeability of the intestinal mucosa have been invoked as cofactors responsible for endotoxemia. At the same time, the evidence that phagocytosis and killing exerted by polymorphonuclear cells and monocytes and the T-cell dependent antibacterial activity are decreased in IBD patients may also explain the origin of LPS in these diseases.
In IBD, pro-inflammatory cytokines and chemokines have been detected in elevated amounts in mucosal tissue and/or in peripheral blood, thus suggesting a monocyte/macrophage stimulation by enteric bacteria and/or their constituents (e.g. LPS).
On these grounds, in experimental models and in human IBD, anti-cytokine monoclonal antibodies and interleukin receptor antagonists are under investigation for their capacity to neutralize the noxious effects of immune mediators. Finally, the administration of lactobacilli is beneficial in human IBD and, in murine colitis, this treatment leads to a normalization of intestinal flora, reducing the number of colonic mucosal adherent and translocated bacteria.
References
1.
Brandtzaeg P. , Baekkevold ES, Farstad IN et al. Regional specialization in the mucosal immune system: what happens in the microcompartments?Immunol Today1999; 20: 141—151.
2.
MacDermott RPImmunology of inflammatory bowel disease. Curr OpinGastroenterol1998; 14: 54—67.
3.
Dalwadi H., Wei B., Braun J.Defining new pathogens and nonculturable infectious agents associated with inflammatory bowel disease. Curr OpinGastroenterol2000; 16: 56—59.
4.
Rickert RR, Carter HWThe `early' ulcerative lesion of Crohn's disease: correlative light and scanning electron-microscopic studies. J Clin Gastroenterol1980; 2: 11—18.
5.
Niessner M., Volk BAAltered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol1995; 101: 28—35.
6.
Sartor RBCytokines in intestinal inflammation: pathophysiological and clinical considerations . Gastroenterology1994; 106: 533—539.
7.
Matsura T., West GA, Klein JSSoluble interleukin-2 and CD8 and CD4 receptors in inflammatory bowel disease . Gastroenterology1992; 102: 2006—2014.
8.
Balzano A., Bove A., Leonardi E. et al. The soluble interleukin-2 receptor as an indicator of clinical evolution in patients with ulcerative colitis. Eur J Gastroenterol Hepatol1997; 9: 173—177.
9.
Burgio VL, Fais S., Boirivant M., Perrone A., Pallone F.Peripheral monocyte and naive T-cell recruitment and activation in Crohn's disease. Gastroenterology1995; 109: 1029—1038.
10.
Lundquist C. , Baranov V., Hammarström S., Athiln L., Hammarström MLIntraepithelial lymphocytes: evidence for regional specialization and extrathymic T-cell maturation in the human gut epithelium. Int Immunol1995; 7: 1473—1480.
11.
Hass W., Pereira P., Tonegawa S.γδ T cells. Annu Rev Immunol1993; 11: 637—659.
12.
Peetermans WE, D'Haens GR, Ceuppens JL, Rutgeerts P., Geboes K.Mucosal expression by B-7 positive cells of the 60-kilodalton heat-shock protein in inflammatory bowel disease. Gastroenterology1995; 108: 75—83.
13.
Söderström K., Bucht A., Halapi E., Grönberg A., Magnusson I., Kiessling R.Increased frequency of abnormal γδ T cells in blood of patients with inflammatory bowel disease. J Immunol1996; 156: 2331—2339.
14.
Brandtzaeg P., Sollid LM, Thrane PSLymphoepithelial interactions in the human mucosal immune system. Gut1988; 29: 1116—1130.
15.
Scott MG, Nahm MH, Macke K.Spontaneous secretion of IgG subclasses by intestinal mononuclear cells: differences between ulcerative colitis, Crohn's disease and controls. Clin Exp Immunol1986; 66: 209—215.
16.
Targan SR, Landers CJ, Cobb L.Perinuclear anti-neutrophil cytoplasmic antibodies are spontaneously produced by mucosal B cells of ulcerative colitis patients. J Immunol1995; 155: 3262—3267.
17.
Saverymuttu SH, Peters AM, Lavender JP, Chadwick VS, Hodgson JHIn vivo assessment of granulocyte migration to diseased bowel in Crohn's disease. Gut1985; 26: 378—383.
18.
Pullman WE, Sullivan PJ, Barrett PJAssessment of inflammatory bowel disease activity by 99mtechnetium phagocyte scanning. Gastroenterology1988; 95: 989—996.
19.
Liu ZX, Hiwatashi N., Noguchi M., Toyota T.Increased expression of costimulatory molecules on peripheral blood monocytes in patients with Crohn's disease. Scand J Gastroenterol1997; 32: 1242—1246.
20.
Rugtveit J. , Nilsen EM, Bakka A., Carlsen H., Brandtzaeg P., Scott H.Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease . Gastroenterology1997, 112: 1493—1505.
Owen RLM cells — entryways of opportunity for enteropathogens. J Exp Med1994; 180: 7—9.
23.
Jensen VB, Harty JT, Jones BDInteractions of the invasive pathogens Salmonella typhimurium, Listeria monocytogenes, and Shigella flexneri with M cells and murine Peyer's patches. Infect Immun1998; 66: 3758—3766.
24.
Boudeau J., Glasser A-L., Masseret E., Joly B., Darfeville-Michaud A.Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect Immun1999; 67: 4499—4509.
25.
Sartor RBMicrobial agents in the pathogenesis, differential diagnosis, and complications of inflammatory bowel disease. In: Blaser M, ed. Infections of the Gastrointestinal Tract. New York, NY: Raven, 1995; 435—458.
26.
Sutherland LJ, Singleton J., Session J.Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut1991 ; 32: 1071—1075.
27.
Tabaqchali S., O'Donoghue DP, Bettelheim KAEscherichia coli antibodies in patients with inflammatory bowel disease. Gut1978; 19: 108—113.
28.
Liu Y., Van Kruningen HJ, West AB, Cartun RW, Cortot A., Colombel JFImmunocytochemical evidence of Listeria, Escherichia coli, and Streptoccoccus antigens in Crohn's disease. Gastroenterology1995; 108: 1396—1401.
29.
Darfeville-Michaud A., Neut C., Barnich E. et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology1998; 115: 1405—1413.
30.
Higgins LM, Frankel G., Douce G., Dougan G., MacDonald TT. Citrobacterium rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease. Infect Immun1999; 67: 3031—3039.
31.
Li X., Fox JG, Whary MT, Yan L., Shames B., Zhao Z.SCID/NCr naturally infected with Helicobacter hepaticus develop progressive hepatitis, proliferative typhlitis and colitis. Infect Immun1998; 66: 5477—5484.
32.
Kullberg MC , Ward JM, Gorelick PL et al. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10) deficient mice through an IL-12-and gamma interferon-dependent mechanism. Infect Immun1998; 66: 5157—5166.
33.
Whary MT, Morgan TJ, Dangler CA, Gaudes KJ, Taylor NS, Fox JGChronic active hepatitis induced by Helicobacter hepaticus in the A/JCr mouse is associated with a Th1 cell-mediated immune response. Infect Immun1998; 66: 3142—3148.
34.
Morgan KLJohne's and Crohn's. Chronic inflammatory bowel diseases of infectious aetiology?Lancet1987; ii: 1017—1018.
35.
Van Der Giessen Jwb, Haring RM, Vauclare E., Eger A., Haagsma J., Van Der Zeijst Bam.Evaluation of the abilities of three diagnostic tests based on polymerase chain reaction to detect Mycobacterium paratuberculosis in cattle: application in a control program. J Clin Microbiol1992; 30: 1216—1219.
36.
Del Prete R., Quaranta M., Lippolis A. et al. Detection of Mycobacterium paratuberculosis in stool samples of patients with inflammatory bowel disease by IS900-based PCR and colorimetric detection of amplified DNA. J Microbiol Methods1998; 33: 105—114.
37.
Cellier C., De Beenhouwer H., Berger A. et al. Mycobacterium paratuberculosis and Mycobacterium avium subsp. silvaticum DNA cannot be detected by PCR in Crohn's disease tissue. Gastroenterol Clin Biol1998; 22: 675—678.
38.
Sellon RK, Tonkonogy S., Schultz M. et al. Resident enteric bacteria are necessary for the development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun1998; 66: 5224—5231.
39.
Shalon LB, Gulwani-Akolkar B., Fisher SE et al. Evidence for an altered T-cell receptor repertoire in Crohn's diseases. Autoimmunity1994; 17: 301—308.
40.
Chott A., Probert CS, Gross GG, Blumberg RS, Balk SPA common TCR-β chain expressed by CD8+ intestinal mucosa T cells in ulcerative colitis. J Immunol1996; 156: 3024—3031.
41.
Probert CS, Chott A., Turner JR et al. Persistent clonal expansions of peripheral blood CD4+ lymphocytes in chronic inflammatory bowel disease. J Immunol1996;157: 3183—3191.
42.
Takahashi I. , Iijima H., Katashima R., Itakura M., Kijono H.Clonal expansion of CD4+ TCR-ββ+ T cells in TCR-α-chain-deficient mice by gut-derived antigens. J Immunol1999; 162: 1843—1850.
43.
Eckmann L., Kagnoff MF, Fierer J.Epithelial cells secrete the chemokine interleukin-8 to bacterial entry. Infect Immun1993; 61: 4569—4574.
44.
Jung HC, Eckmann L., Yang SK et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest1995; 95: 55—65.
45.
McCormick BA , Miller SI, Carnes D., Madara JLTransepithelial signaling to neutrophils by Salmonellae: a novel virulence mechanism for gastroenteritis. Infect Immun1995; 63: 2302—2309.
46.
Yang SK, Eckmann L., Panja A., Kagnoff MFDifferential and regulated expression of CXC, CC and C-chemokines by human colon epithelial cells. Gastroenterology1997 ; 113: 1214—1223.
47.
Elewaut D., Didonato JA, Kim JM et al. Nuclear factor-κB is a central regulator of the epithelial cell proinflammatory gene program after infection with invasive bacteria. Gastroenterology1999; 116: G3071.
48.
Ohno Y., Lee J., Fusunyan RD, MacDermott RP, Sanderson IRMacrophage inflammatory protein-2: chromosomal regulation in rat small intestinal epithelial cells. Proc Natl Acad Sci USA1997 ; 94: 10279—10284.
49.
MacDermott RPChemokines in the inflammatory bowel diseases . J Clin Immunol1999; 19: 266—272.
50.
Levin J., Poore TE, Zauber NP, Oser RSDetection of endotoxin in the blood of patients with sepsis due to Gram-negative bacteria. N Engl J Med1970; 283: 1313—1316.
51.
Novitsky TJLimulus amebocyte lysate (LAL) detection of endotoxin in human blood. J Endotoxin Res1994; 1: 253—263.
52.
Jirillo E., Caradonna L., Greco B. et al. Circulating bacterial lipopolysaccharides (LPS) in patients with inflammatory bowel disease. Microecol Ther1995; 25: 37—41.
53.
Amati L., Caradonna L., Jirillo E., Caccavo D.Immunological disorders in inflammatory bowel disease and immunotherapeutic implications. Ital J Gastroenterol Hepatol1999; 31: 313—325.
54.
Caradonna L. , Amati L., Lella P., Jirillo E., Caccavo D.Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxin in inflammatory bowel disease. Am J Gastroenterol2000; 95: 1495—1502.
55.
Colin R., Grancher T., Lemeland JF et al. Endotoxemia in patients with inflammatory bowel enterocolitis . Gastroenterol Clin Biol1979; 3: 15—19.
56.
Juhlin L., Krause V., Shelley WBEndotoxin-induced microclots in ulcerative colitis and Crohn's disease. Scand J Gastroenterol1980; 15: 311—314.
57.
Aoki KAStudy of endotoxemia in ulcerative colitis and Crohn's disease. Acta Med Okayama1978; 32: 147—158.
58.
Liehr H.Endotoxins and the pathogenesis of hepatic and gastrointestinal diseases. In: MMW Munch Med Wochenschr1981; 123: 53—55.
59.
Wellmann W. , Fink PC, Benner F., Schmidt FWEndotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid. Gut1986; 27: 814—820.
60.
Wyatt J., Vogelsang H., Hubl W., Waldhoe T., Lochs H.Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet1993; 341: 1437—1439.
61.
De Simone C. , Vesely R., Bianchi Salvadori B, Jirillo E.The role of probiotics in modulation of the immune system in man and animals. Int J Immunother1993; 9: 23—28.
62.
Fabia R., Ar'rajab A., Johansson ML et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion1993; 54: 248—255.
63.
Favier C., Neut C., Milon C., Cortot A., Colombel JF, Milon J.Fecal β-D-galactosidase production and bifidobacteria are decreased in Crohn's disease. Dig Dis Sci1997; 42: 817—822.
64.
Ruseler-Van-Embden Jgh, Schouten WR, Van Lieshout Lmc.Pouchitis: result of microbial imbalance . Gut1994; 35: 658—664.
65.
Jirillo E., Caradonna L., Greco B. et al. Cellular immunity in steroid-treated patients with inflammatory bowel diseases. Med Sci Res1995; 23: 355—357.
66.
Antonaci S. , Tortorella C., De Simone C., Jirillo E.Role of bacterial lipopolysaccharides in the development of natural antibacterial activity mediated by human peripheral blood T lymphocytes. Int Rev Immunol1990; 6: 237—245.
67.
Amati L., Caradonna L., Greco B., Leandro G., Caccavo D., Jirillo E.Impairment of cellular immune responsiveness in relatives of patients affected by ulcerative colitis. Gastroenterology1998 ; 114: AG3769.
68.
Fiocchi C.Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology1998; 115: 182—205.
69.
Jirillo E., Amati L., Caradonna L. et al. Soluble(s) CD14 and plasmatic lipopolysaccharides (LPS) in patients with chronic hepatitis C before and after treatment with interferon α . Immunopharmacol Immunotoxicol1998; 20: 1—14.
70.
Amati L., Caradonna L., Greco B., Leo S., Caccavo D., Jirillo E.Impairment of phagocytic and T-cell mediated antibacterial activity and plasma endotoxin in patients with untreated gastrointestinal cancer. Scand J Gastroenterol1998; 33: 847—852.
71.
Peen E., Almer S., Bodemar G. et al. Antilactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangiatis, and Crohn's disease. Gut1993; 34: 56—62.
72.
Sanchez L., Calvo M., Brock JHBiological role of lactoferrin. Arch Dis Child1992; 67: 657—661.
73.
Caccavo D., Afeltra A., Pece S. et al. Lactoferrin-lipid A-lipopolysaccharide interaction: inhibition by anti-human lactoferrin monoclonal antibody AGM 10.14. Infect Immun1999; 67: 4668—4672.
74.
Elass-Rochard E., Legrand D., Salmon V. et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide binding-protein . Infect Immun1998; 66: 486—491.
75.
Yang RB, Mark MR, Gurney AL, Godowski PJSignaling events induced by lipopolysaccharide-activated tool-like receptor 2. J Immunol1999; 163: 639—647.
76.
Mahida YR, Wu K., Jewell DPEnhanced production of interleukin 1-β by mononuclear cells isolated from mucosa with active ulcerative colitis and Crohn's disease. Gut1989; 30: 835—838.
77.
Youngman KR, Simon PL, West GA et al. Localization of intestinal interleukin 1 activity, protein and gene expression to lamina propria cells. Gastroenterology1993; 104: 749—758.
78.
Reinecker H-C. , Steffen M., Witthoeft T. et al. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol1993; 94: 174—181.
79.
MacDonald TT , Hutchings P., Choy M-Y., Murch S., Cooke A.Tumor necrosis factor-α and interferon-gamma production measured at the single cell level in normal and inflamed human intestine. Clin Exp Immunol1980; 81: 1301—1307.
80.
Cappello M. , Keshav S., Prince C., Jewell DP, Gordon S.Detection of mRNA for macrophage products in inflammatory bowel disease by in situ hybridization. Gut1992; 33: 1214—1219.
81.
Stevens C., Walz G., Singaram C. et al. Tumor necrosis factor-α, interleukin-1β, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci1992; 37: 818—826.
82.
Braegger CP , Nicholls S., Murch SM, Stephens S., MacDonald TTTumor necrosis factor-alpha in stool as a marker of intestinal inflammation. Lancet1992; 339: 89—91.
83.
Ahnfelt-Ronne I., Nielsen OH, Christensen A., Langholz E., Binder V., Riis P.Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology1990; 98: 1162—1169.
84.
McKenzi SJ, Buffinton JD, Baker MS, Doe WFColonic epithelial cell glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a target of deoxydative injury in inflammatory bowel disease (IBD). Gastroenterology1993; 104: A741.
Sartor RBCytokines in intestinal inflammationpathophysiologic and clinical considerations . Gastroenterology1994;106: 533—537.
87.
Middleton SJ , Shorthouse M., Hunter JOIncreased nitric oxide synthesis in ulcerative colitis. Lancet1993; 341: 465—466.
88.
Huang KT, Kuo L., Liao JLLipopolysaccharide activates endothelial nitric oxide synthase through protein tyrosine kinase. Biochem Biophys Res Commun1998; 245: 33—37.
89.
Serio M., Potenza MA, Montagnani M. et al. Bacterial lipopolysaccharide-induced hyporeactivity in perfused rat resistance vessels: modulating effects of dexamethasone. J Endotoxin Res1996; 3: 491—496.
90.
Casini-Raggi V., Kam L., Chong Yjt, Fiocchi C., Pizarro TT, Cominelli F.Mucosal imbalance of interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease: a novel mechanism of chronic inflammation. J Immunol1995; 154: 2434—2440.
91.
Cominelli F. , Nast CC, Clark BDInterleukin-1 (IL-1) gene expression, synthesis and effect of specific IL-1 receptor blockade in rabbit immune complex colitis . J Clin Invest1990; 86: 972—980.
92.
Hirv K., Seyfarth M., Uibo R. et al. Polymorphisms in tumor necrosis factor and adhesion molecule genes in patients with inflammatory bowel disease: association with HLA-DR and —DQ alleles and subclinical markers. Scand J Gastroenterol1999, 34: 1025—1032.
93.
Nemetz A., Köpe T., Molnar T. et al. Significant differences in the interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms in a Hungarian population with inflammatory bowel disease. Scand J Gastroenterol1999, 34: 175—179.
94.
Targan SR, Hanaver SB, Van Deventer Sjh, Mayer L., Present DH, Braakman T.A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α in Crohn's disease. N Engl J Med1997; 337: 1029—1035.
95.
Rutgeerts P. , D'Haens G., Van Deventer Sjh and the Crohn's Disease cA2 Study Group.Retreatment with anti-TNFα chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease . Gastroenterology1997; 112: A1078.
96.
Stack WA, Mann SD, Roy AJ, Heat P., Sopwith M., Freeman J.Randomised controlled trial of CDP571 antibody to tumor necrosis factor α in Crohn's disease. Lancet1997; 349: 521—524.
97.
Pallone F., Monteleone G.Interleukin 12 and Th1 responses in inflammatory bowel disease. Gut1998; 43: 735—736.
98.
Monteleone G., Biancone L., Marasco R. et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology1997; 112: 1169—1178.
99.
Neurath MF, Fuss I., Kelsall BL, Stüber E., Strober W.Antibodies to IL-12 abrogate established experimental colitis in mice. J Exp Med1995; 182: 1281—1290.
100.
Fuss IJ, Marth T., Neurath MF, Pearlstein GR, Jain A., Strober W.Anti-interleukin 12 treatment regulates apoptosis of Th1 cells in experimental colitis in mice. Gastroenterology1999; 117: 1078—1088.
101.
Ehrhardt RO , Ludviksson BR, Gray B., Neurath M., Strober W.Induction and prevention of colonic inflammation in IL-2 deficient mice. J Immunol1997; 158: 566—573.
102.
Pizarro TT , Michie MH, Bentz M. et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J Immunol1999; 162: 6829—6835.
103.
Mosmann TRProperties and function of interleukin-10. Adv Immunol1994; 56: 1—16.
104.
Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W.Interleukin-10-deficient mice develop chronic enterocolitis. Cell1993; 75: 263—274.
105.
Groux H., Powrie F.Regulatory T cells and inflammatory bowel disease. Immunol Today1999; 20: 442—446.
106.
Neurath MF , Fuss I., Kelsall BL, Presky DH, Waegell L., Strober W.Experimental granulomatous colitis in mice is abrogated by induction TGF-β-mediated oral tolerance. J Exp Med1996; 183: 2605—2616.
Hagenbaugh A., Sharma S., Dubinett SM et al. Altered immune responses in interleukin 10 transgenic mice. J Exp Med1997; 185: 2101—2110.
109.
Barbara G. , Hogaboam CM, Gauldie J., Collins SMInterleukin 10 gene therapy prevents the occurence but doesn't reverse experimental colitis. Gastroenterology1997; 112: A927.
110.
Van Deventer Sjh, Elson CO, Fedorak RNMultiple dose of intravenous interleukin-10 in steroid-refractory Crohn's disease. Gastroenterology1997; 113: 383—389.
111.
Neurath MF , Petterson S., Meyer Zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothidate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med1996; 2: 998—1004.
112.
De Simone C., Ciardi A., Grassi A. et al. Effect of Bifidobacterium bifidium and Lactobacillus acidophilus on gut mucosa and peripheral blood B lymphocytes . Immunopharmacol Immunotoxicol1992; 14: 331—340.
113.
Isolauri E.Probiotics and gut inflammation. Curr Opin Gastroenterol1999; 15: 534—537.
114.
Campieri M., Gionchetti P.Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative. Gastroenterology1999; 116: 1246—1260.
115.
Gionchetti P. , Rizzello F., Venturi A. et al. Maintenance treatment of chronic pouchitis: a randomized, placebo-controlled, double-blind trial with a new probiotic preparation. Gastroenterology1998; 114: G4037, p. A985.
116.
Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RNLactobacillus species prevents colitis in interleukin 10 gene-deficient mice . Gastroenterology1999; 116: 1107—1114.
117.
Dugas B., Mercenier A., Wijnkoop IL et al. Immunity and probiotics. Immunol Today1999; 20: 387—390.
118.
Kruis W., Schussler P., Weinzierl M., Galanos C., Eisenburg J.Circulating lipid A antibodies despite absence of systemic endotoxemia in patients with Crohn's disease. Dig Dis Sci1984; 29: 502—507.
119.
Broberger O., Perlmann P.Autoantibodies in human ulcerative colitis . J Exp Med1959; 110: 657—674.
120.
Perlmann P. , Hammarstrom S., Lagercrantz R., Campbell D.Autoantibodies to colon in rats and human ulcerative colitis: cross reactivity with Escherichia coli 0:14 antigen. Proc Soc Exp Biol Med1967; 125: 975—980.
121.
Seibold F. , Brandwein S., Simpson S., Terhost C., Elson COpANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol1998; 18: 153—160.
122.
Cohavy O., Harth G., Horwitz M. et al. Identification of a novel mycobacterial histone H1 homologue (Hup B) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulins from patients with Crohn's disease. Infect Immun1999; 67: 6510—6517.
123.
Cohavy O., Bruckner D., Gordon LK et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun2000; 68: 1542—1548.
Hershberg RM, Mayer LFAntigen processing and presentation by intestinal epithelial cells. Polarity and complexity. Immunol Today2000; 21: 123—128.
126.
Jirillo E. , Greco B., Caradonna L., Rembouskos G., Di Leo A., Giorgio I.Role of immune networks in inflammatory bowel diseases (IBD) with special reference to ulcerative colitis and Crohn's disease: a proposal for a new pathogenic model of IBD. EOS J Immunol Immunopharmacol1994; 14: 121—131.
